Randomized study of granulocyte colony stimulating factor for childhood B-cell non-Hodgkin lymphoma: a report from the Japanese pediatric leukemia/lymphoma study group B-NHL03 study

References

• Reiter A, Schrappe M, Tiemann M, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: reports of the Berlin-Frankfurt-Münster Group trial NHL-BFM 90. Blood 1999; 94: 3294–3306.
   PubMed Web of Science ®Google Scholar
• Patte C, Auperin A, Michon J, et al. The Société Française d’Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 2001; 97: 3370–3379.
   PubMed Web of Science ®Google Scholar
• Patte C, Auperin A, Gerrard M, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents. It is possible to reduce treatment for the early responding patients. Blood 2007; 109: 2773–2780.
   PubMed Web of Science ®Google Scholar
• Tsurusawa M, Mori T, Kikuchi A, et al. Improved treatment results of children with B-cell non-Hodgkin lymphoma: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group B-NHL03 Study. Pediatr Blood Cancer 2014; 61: 1215–1221.
   PubMed Web of Science ®Google Scholar
• Gabrilove JL, Jakubowski A, Scher H, et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 1998; 318: 1414–1422.
   Web of Science ®Google Scholar
• Morstyn G, Campbell L, Souza LM, et al. Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet 1988; 1: 667–672.
   PubMed Web of Science ®Google Scholar
• Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991; 325: 164–170.
   PubMed Web of Science ®Google Scholar
• Trillet-Lenoir V, Green J, Manegold C, et al. Recombinant granulocyte colony-stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993; 29A: 319–324.
   PubMed Web of Science ®Google Scholar
• American Society of Clinical Oncology. Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 1996; 14: 1957–1960.
   PubMed Web of Science ®Google Scholar
• Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24: 3187–3205.
   PubMed Web of Science ®Google Scholar
• Kouroukis CT, Chia S, Verma S, et al. Canadian supportive  care recommendations for the management of neutropenia in patients with cancer. Curr Oncol 2008; 15: 9–23.
   PubMed Web of Science ®Google Scholar
• Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011; 47: 8–32.
   PubMed Web of Science ®Google Scholar
• Pettengell R, Aapro M, Brusamolino E, et al. Implications of the European Organisation for Research and Treatment of Cancer (EORTC) guidelines on the use of granulocyte colony-stimulating factor (G-CSF) for lymphoma care. Clin Drug Invest 2009; 29: 491–513.
   PubMed Web of Science ®Google Scholar
• Kansara R, Kumar R, Seftel M. Is primary prophylaxis with granulocyte colony stimulating factor (G-CSF) indicated in the treatment of lymphoma? Transfus Apher Sci 2013; 49: 51–55.
   PubMed Web of Science ®Google Scholar
• Rubino C, Laplanche A, Patte C, et al. Cost-minimization analysis of prophylactic granulocyte colony-stimulating factor after induction chemotherapy in children with non-Hodgkin's lymphoma. J Natl Cancer Inst 1998; 90: 750–755.
   PubMedGoogle Scholar
• Patte C, Laplanche A, Bertozzi AI, et al. Granulocyte colony-stimulating factor in induction treatment of children with non-Hodgkin's lymphoma: a randomized study of the French Society of Pediatric Oncology. J Clin Oncol 2002; 20: 441–448.
   PubMed Web of Science ®Google Scholar
• Welte K, Riehm H. Granulocyte colony-stimulating factor in children with acute lymphoblasticleukemia. N Engl J Med 1997; 337: 1320–1321.
   PubMed Web of Science ®Google Scholar
• Sarashina T, Kobayashi R, Yoshida M, et al. A randomized trial of cefozopran versus cefepime as empirical antibiotic treatment of febrile neutropenia in Pediatr cancer patients. Pediatric Blood Cancer 2014; 61: 1992–1995.
   PubMed Web of Science ®Google Scholar
• Welte K, Reiter A, Mempel K, et al. A randomized phase III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Blood 1996; 87: 3143–3150.
   PubMed Web of Science ®Google Scholar
• Laver J, Amylon M, Desai S, et al. Randomized trial of r-metHu granurocyte colony-stimulating factor in an intensive treatment for T-cell leukemia and advanced-stage lymphoblastic lymphoma of childhood: a Pediatric Oncology Group pilot study. J Clin Oncol 1998; 16: 522–526.
   PubMed Web of Science ®Google Scholar
• Clarke V, Dunstan FD, Webb DK. Granulocyte colony-stimulating factor ameliorates toxicity of intensification chemotherapy for acute lymphoblastic leukemia. Med Pediatr Oncol 1999; 32: 331–335.
   PubMedGoogle Scholar
• Michel G, Landman-Parker J, Auclerc MF, et al. Use of recombinant human granulocyte colony-stimulating factor to increase chemotherapy dose intensity: a randomized trial in very high-risk childhood acute lymphoblastic leukemia. J Clin Oncol 2000; 18: 1517–1524.
   PubMed Web of Science ®Google Scholar
• Saarinen-Pihkala UM, Lanning M, Perkkiö M, et al. Granulocyte-macrophage colony-stimulating factor support in therapy of high-risk acute lymphoblastic leukemia in children. Med Pediatr Oncol 2000; 34: 319–327.
   PubMedGoogle Scholar
• Heath JA, Steinherz PG, Altman A, et al. Human granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia: a Children’s Cancer Group study. J Clin Oncol 2003; 21: 1612–1617.
   PubMed Web of Science ®Google Scholar
• Pui CH, Boyett JM, Hughes WT, et al. Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med 1997; 336: 1781–1787.
   PubMed Web of Science ®Google Scholar
• Bennett CL, Stinson TJ, Lane D, et al. Cost analysis of filgrastim for the prevention of neutropenia in pediatric T-cell leukemia and advanced lymphoblastic lymphoma: a case for prospective economic analysis in cooperative group trials. Med Pediatr Oncol 2000; 34: 92–96.
   PubMedGoogle Scholar